
A New Biosimilar to Remicade in the Fray
Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.
The market value of Remicade, Enbrel, and Humira could dwindle if Celltrion’s biosimilar to Remicade—deemed “highly similar” to the reference product by the FDA—is approved.
According to a
The scientists state in their report that Remsima is highly similar to Remicade in treating rheumatoid arthritis and ankylosing spondylitis, and that there are only minor differences in clinically inactive components.
If approved, this will be just the second biosimilar to enter the market after Zarxio, which was
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.